GENE ONLINE|News &
From Forbidden Drugs to Psychotropic Cures: A “Psychedelic Boom” Breaks New Ground in Treating Mental Illnesses
More than 30% of adults worldwide have experienced generalized anxiety disorder and 5% suffer from depression, not including the population with other mental illnesses such as attention deficit hyperactivity disorder (ADHD) or post-traumatic stress disorder (PTSD).
Based on statistics, the estimated revenue of the U.S. mental health market was $397.4 billion and the global market size is expected to grow to more than $500 billion by 2030.
The market growth has brought about the rise of novel treatments. Psychedelics, a family of highly controversial drugs, are being gradually destigmatized and attracting attention from scientists and investors. What are the most common psychedelics?
Based on statistics, the estimated revenue of the U.S. mental health market was $397.4 billion and the global market size is expected to grow to more than $500 billion by 2030.
The market growth has brought about the rise of novel treatments. Psychedelics, a family of highly controversial drugs, are being gradually destigmatized and attracting attention from scientists and investors. What are the most common psychedelics?
GO Prime with only $1.49 now
LATEST
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
